
## **ASX Announcement**





## **INOVIQ** receives \$1m R&D Tax Incentive Refund

INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) is pleased to announce that it has received a \$1.018m Research & Development (R&D) Tax Incentive refund relating to its FY24 R&D activities.

The Australian Government's R&D Tax Incentive program provides companies with a 43.5% refundable tax offset for eligible R&D activities. INOVIQ incurred \$2.7m on R&D activities in FY24 and was able to claim the refund on eligible expenditure which excluded certain overseas based expenditure.

Authorised for release by Company Secretary, Mark Edwards.

## **FURTHER INFORMATION**

Dr Leearne Hinch	David Williams
Chief Executive Officer	Chairman
E <u>lhinch@inoviq.com</u>	E <u>dwilliams@kidder.com.au</u>
<b>M</b> +61 400 414 416	<b>M</b> +61 414 383 593

## **ABOUT INOVIQ LTD**

INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours. For more information on INOVIQ, visit <u>www.inoviq.com</u>.

